Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Ischemic Stroke Recovery

0
TXA127 Phase 2 Clinical Trial for Ischemic Stroke Recovery

The first patient is dosed in Constant Therapeutics' phase 2 clinical trial for TXA127, a potential treatment for ischemic stroke recovery. The trial, conducted at Sheba Medical Center, aims to address the unmet medical need for chronic stroke treatment.

Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient has been dosed in the Company’s phase 2 clinical trial of TXA127, the Company’s lead peptide product under development as a potential treatment for ischemic stroke recovery.

The phase 2 trial is a randomized, placebo-controlled, double-blind, hybrid decentralized study designed to evaluate the safety and efficacy in ischemic stroke patients who are 18 to 85 years old and who are 6 to 24 months post stroke event. Patients will receive 3 months of treatment. The study is being conducted in Israel at Sheba Medical Center in collaboration with Sabar Health for the home visits, and it is expected to enroll 50 patients.

“There are no drugs available to treat chronic stroke, but the design and logistics of clinical trials in these patients is particularly difficult. We are fortunate to have been able to put together the infrastructure needed, with the participation of Sabar Health and Sheba Medical Center. This unique combination will allow us to test TXA127 for this important unmet medical need,” said Rick Franklin, CEO of Constant Therapeutics.”

Author

Leave a Reply

Your email address will not be published.